Impact of iron hydroxide (III) on level of postoperative anemia in patients with combined mitral and aortal heart failures
Objective. To investigate a combined impact of iron hydroxide (III) on the anemia level after prosthesis of mitral and aortal valves in accordance to the blood-preserving technology in conditions of artificial blood circulation.
Materials and methods. In 52 patients with combined mitral-aortal heart failures the levels of hemoglobin, hematocrit, iron and enzymes were investigated. Group C of the patients was delineated with anemia in chronic diseases and low values of levels of iron, ferritin, hemoglobin, hematocrit, in whom preoperatively correction of low iron content in the blood serum was conducted. After preoperative correction, using iron hydroxide (III), in patients of the Group C the mitral and aortal valves prosthesis was conducted, applying the blood-securing technology. The patients, in whom the levels of hemoglobin, hematocrit, erythrocytes, iron were in normal range, were put into Groups A and B.The Group A patients were operated with application of the donor’s blood, and the Group B - without application of the donor’s blood in accordance to the blood-preserving technology.
Results. The investigations conducted have shown, that big volumes ot the donor’s blood components - (653.0 ± 118.0) ml of erythrocytic mass and (728.0 ± 63.0) ml of fresh-frozen plasm - were transfused to the Group A patients for stabilization of postoperative level of hemoglobin and hematocrit. Performance of operations of the mitral and aortal prosthesis in accordance to the blood-preserving technology is possible without transfusion of the donor’s blood preparations, but lowering of the hemoglobin level by 19.5%, hematocrit - by 13.2%, erythrocytes - by 15.8%, the serum iron - by 17.9%, thrombocytes - by 31.4% in the Group B patients indicates the necessity for provision of the donor’s blood components preoperatively. Preoperative correction of the serum level of iron in the Group C patients with anemia due to chronic diseases have raised its its preoperative level in 9.8 times and the level of hemoglobin - by 8.0%. Combination of preoperative correction of the blood serum level of the iron with intraoperative application of the blood-preserving technology during procedure for the mitral and aortal valves in patients of Group C have reduced anemia in accordance to data of hemoglobin level in postoperative period by 9.3%, and thrombocytopenia - by 9.5%.
Conclusion. Combination of preoperative correction of anemia due to chronic diseases using iron hydroxide (III) with application of the blood-preserving technologies while doing operations of the mitral and aortal valves prosthesis reduces the postoperative anemia level by 9.3%.
Hubutiya MSh, Solonin SA, Bazhenov AI, Kobzeva EN, Smirnova YuV, Godkov MA. Risks of transmission of blood-borne viral infections via blood transfusion, organ and tissue transplantation. Transplantologiya. 2015;(4):23-33. [In Russian].
Humeniuk BM. Vyiavlennia markeriv infektsii, shcho peredaiutsia cherez krov u donoriv ta patsiientiv kardiokhirurhichnoho statsionaru. Shchorichnyk naukovykh prats Asotsiatsii sertsevo-sudynnykh khirurhiv Ukrainy. 2012;20:122-5. [In Ukrainian].
Lewis CE, Hiratzka LF, Woods SE, Hendy MP, Engel AM. Autologous blood transfusion in elective cardiac valve operations. J Card Surg. 2005;20(6):513-8. doi:10.1111/j.1540-8191.2005.00137.x.
Hematolohiia i perelyvannia krovi. Mizhvidomchyi zbirnyk. Vyp. 38. Kyiv: MPBP “GORDON”; 2015. 495 s.
Kozek-Langenecker SA, Ahmed AB, Afshari A, Albaladejo P, Aldecoa C, Barauskas G, et al. Management of severe perioperative bleeding: guidelines from the European Society of Anaesthesiology: first update 2016. Eur J Anaesthesiol 2017;34(6):332-95. PMID: 28459785. doi: 10.1097/EJA.0000000000000630.
Naito Y, Tsujino T, Matsumoto M, Sakoda T, Ohyanagi M, Masuyama T. Adaptive response of the heart to long-term anemia induced by iron deficiency. Am J Physiol Heart Circ Physiol. 2009; 296(3):H585-93. PMID: 19136608 doi: 10.1152/ajpheart.00463.2008.
Anker SD, Comin Colet J, Filippatos G, Willenheimer R, Dickstein K, Drexler H, et al. Ferric carboxymaltose in patients with heart failure and iron deficiency. N Engl J Med. 2009;361(25):2436-48. doi: 10.1056/NEJMoa0908355.
Curley GF, Shehata N, Mazer CD, Hare GM, Friedrich JO. Transfusion triggers for guiding RBC transfusion for cardiovascular surgery: a systematic review and meta-analysis Crit Care Med. 2014;42(12):2611-24. doi: 10.1097/CCM.0000000000000548.
Popov VV, Gumenyuk BN, Gurtovenko AM, Dyachenko VL, Tihonenko LI, Rudenko EV, et al. Bloodreserving technology during surgical treatment of mitral valve disease. Bulletin of Cardiovascular Surgery. 2016;(3):44-50. [In Ukrainian].
Dolynna OV. Pathogenesis and ways of correcting anemia syndrome in patients with chronic heart failure. Family medicine. 2016;(1):58-62. doi: 10.30841/2307-5112.1(63).2016.102096.[In Ukrainian].
Uskach TM, Kochetov AG, Tereshchenko SN. The Statistical Analysis of Prevalence of Anemia in Patients With Chronic Heart Failure. Kardiologiia. 2011;51(1):11-7. PMID: 21626796. [In Russian].
O'Meara E, Clayton T, McEntegart MB, McMurray JJ, Lang CC, Roger SD, et al. Clinical Correlates and Consequences of Anemia in a Broad Spectrum of Patiens with Heart Failure Results of the Candesartan in Heart Failure: Assessment of Reduction in Mortality and Morbidity (CHARM) Program. Circulation. 2006;113(7):986-94. doi: 10.1161/CIRCULATIONAHA.105.582577.
This work is licensed under a Creative Commons Attribution 4.0 International License.